Drugmaker GlaxoSmithKline has voluntarily paused enrolment and vaccination in the GRACE phase III trial evaluating its potential respiratory syncytial virus maternal vaccine candidate, as well as two other trials of the candidate in pregnant women.
GlaxoSmithKline said on Friday that the decision was made following a recommendation from the Independent Data Monitoring Committee based on an observation from a routine safety assessment.
The FTSE 100-listed firm stated the decision would not impact its ongoing AReSVi 006 phase III trial for RSV older adults, which remains on track with an anticipated data readout in the first half of 2022.
As of 0835 GMT, GlaxoSmithKline shares had inched back 0.33% to 1,574.35p.
